Hong Kong Building Stock News

SEHK:2356
SEHK:2356Banks

Dah Sing Banking Group (SEHK:2356) Is Up 7.4% After Stronger 2025 Earnings Per Share Results - Has The Bull Case Changed?

Dah Sing Banking Group Limited has reported its full-year 2025 results, with net interest income rising to HK$5,828.67 million and net income reaching HK$2,475.81 million, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year. The earnings release highlights stronger profitability per share, suggesting improved efficiency in converting revenue into shareholder earnings across Dah Sing Banking Group’s core banking operations. Next, we...
SEHK:3698
SEHK:3698Banks

Asian Dividend Stocks Yielding Up To 5.1%

As geopolitical tensions and energy price volatility continue to shape global market sentiment, Asian markets are navigating these challenges with varying impacts on their economies and stock performances. In this complex environment, dividend stocks in Asia stand out as a potential source of steady income, offering investors a degree of stability amid market fluctuations.
SEHK:3788
SEHK:3788Metals and Mining

Assessing Hanking Gold International (SEHK:3788) Valuation After Earnings Softness And New Board Appointment

Hanking Gold International (SEHK:3788) drew attention after its 2025 earnings showed revenue of CNY 2,559.5 million and net income of CNY 172.15 million, alongside the board appointment of experienced mining executive Dr. Tim Sun. See our latest analysis for Hanking Gold International. The share price has picked up momentum recently, with a 14.83% 7-day share price return and 11.27% 90-day share price return, while the 1-year total shareholder return is very large. If earnings releases and...
SEHK:2616
SEHK:2616Biotechs

A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Encouraging CS2009 Trial Results And Wider Losses

CStone Pharmaceuticals (SEHK:2616) has drawn fresh attention after reporting detailed Phase I/II data for CS2009, its trispecific antibody, alongside full year 2025 results that show CNY 269.58 million in sales and a CNY 437 million net loss. See our latest analysis for CStone Pharmaceuticals. The encouraging CS2009 data appears to be feeding into a strong shift in sentiment, with a 1 day share price return of 5.04% and a 7 day share price return of 40.68% at HK$8.75. Momentum has been...
SEHK:1378
SEHK:1378Metals and Mining

China Hongqiao Group (SEHK:1378) Is Up 12.9% After Lifting Its Final Dividend Proposal – Has The Bull Case Changed?

China Hongqiao Group reported its full-year 2025 results on 20 March 2026, with sales of CNY 162.35 billion and net income of CNY 22.64 billion, and proposed a final ordinary dividend of HK$1.65 per share for shareholder approval in May 2026. Alongside steady earnings, the company’s decision to raise its final dividend payout highlights a focus on returning cash to shareholders while maintaining operational scale. We will now examine how China Hongqiao Group’s higher final dividend proposal...